Clinical Trials Logo

Advanced Malignant Neoplasm clinical trials

View clinical trials related to Advanced Malignant Neoplasm.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06394713 Not yet recruiting - Clinical trials for Advanced Malignant Neoplasm

A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors

Start date: June 15, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is designed to evaluate the safety and efficacy of QLF31907 combination therapy in advanced malignant tumors.

NCT ID: NCT06297642 Not yet recruiting - Clinical trials for Advanced Malignant Neoplasm

TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.

Start date: April 2024
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety and efficiency of TQB2928 injection combined with Penpulimab in the treatment of patients with advanced malignant tumors.

NCT ID: NCT06165822 Not yet recruiting - Clinical trials for Advanced Malignant Neoplasm

A Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets

Start date: December 2023
Phase: Phase 1
Study type: Interventional

This is a single-center, open, single-dose, self-controlled phase I clinical trial to evaluate the effects of Itraconazole Capsules/Rifampicin Capsules on pharmacokinetics of TQB3909 tablets in vivo, and the safety of TQB3909 tablets and combined with Itraconazole Capsules/Rifampicin Capsules after single oral dose.

NCT ID: NCT05997342 Not yet recruiting - Clinical trials for Advanced Malignant Neoplasm

A Clinical Study of TQB3912 Tablets in Patients With Advanced Malignant Tumor

Start date: August 2023
Phase: Phase 1
Study type: Interventional

This is a study to evaluate the maximum tolerated dose (MTD), occurrence of all adverse events (AEs) and serious adverse events (SAEs), pharmacokinetic parameters and antitumor effect of TQB3912 tablets in Chinese adult patients with advanced malignant neoplasm. The study was divided into phase Ia and phase Ib, Phase Ia: Dose escalation period, to evaluate the safety and tolerability of TQB3912 tablets, determine MTD; Phase Ib: Effectiveness exploration period, to expand the safe and effective dose group, and to recommend appropriate dosage and method for subsequent clinical research.